{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:10:47Z","timestamp":1794370247873,"version":"4.9.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,13]],"date-time":"2027-05-13T00:00:00Z","timestamp":1810166400000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.resinv.2026.101446","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:49:22Z","timestamp":1778762962000},"page":"101446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical features, pathogenesis, and treatment of anti-MDA5 antibody-positive interstitial lung disease"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-2046","authenticated-orcid":false,"given":"Koichi","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101446_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/ar3097","article-title":"Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management","volume":"12","author":"Castelino","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101446_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0210-2022","article-title":"Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis","volume":"32","author":"Joy","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2026.101446_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101446_bib5","series-title":"Seminars in arthritis and rheumatism","article-title":"Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: a meta-analysis and systematic review","author":"Xie","year":"2023"},{"key":"10.1016\/j.resinv.2026.101446_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system","volume":"8","author":"Hu","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/mr\/road042","article-title":"Predicting the death of patients with anti-melanoma differentiation\u2013associated protein-5-positive dermatomyositis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"34","author":"Yang","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3899\/jrheum.2023-0371","article-title":"Long-term prognosis of antimelanoma differentiation\u2013associated gene 5\u2013positive dermatomyositis with interstitial lung disease","volume":"50","author":"Sasai","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/rheumatology\/keae011","article-title":"Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"64","author":"Ida","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11926-025-01188-7","article-title":"Anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis: recent progress in pathophysiology and treatment","volume":"27","author":"Yoshida","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.resinv.2026.101446_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/ar3547","article-title":"Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan","volume":"13","author":"Muro","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101446_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001202","article-title":"Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease","volume":"6","author":"Nishina","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.resinv.2026.101446_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102788","article-title":"The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger","volume":"20","author":"Toquet","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.resinv.2026.101446_bib17","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1093\/rheumatology\/keab224","article-title":"Anti-MDA-5-positive dermatomyositis associated rapidly progressive interstitial lung disease, a virus-triggered autoimmune-like symptom?","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib18","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief report: association of HLA\u2013DRB1\u2217 0101\/\u2217 0405 with susceptibility to anti\u2013melanoma differentiation\u2013associated gene 5 antibody\u2013positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2026.101446_bib19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","article-title":"Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis","volume":"77","author":"Kochi","year":"2018","journal-title":"Annals of the rheumatic diseases"},{"key":"10.1016\/j.resinv.2026.101446_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-10895-1","article-title":"Dysregulated type I\/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis","volume":"15","author":"Yoshida","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2026.101446_bib21","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/1346-8138.16772","article-title":"Age distribution and prevalence in different age groups of four myositis\u2010specific autoantibodies, including anti\u2010ARS, anti\u2010MDA5, anti\u2010Mi\u20102, and anti\u2010TIF1\u03b3 antibodies","volume":"50","author":"Ueda\u2010Hayakawa","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.resinv.2026.101446_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.837024","article-title":"Seasonal effect on disease onset and presentation in anti-MDA5 positive dermatomyositis","volume":"9","author":"So","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib23","first-page":"309","article-title":"Anti-MDA5-positive dermatomyositis and remission in a single referral center population","volume":"41","author":"Tiniakou","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2024869","article-title":"Predictors of poor outcome of anti\u2010MDA5\u2010associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis","volume":"2020","author":"Li","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.resinv.2026.101446_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14397595.2020.1740400","article-title":"Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age","volume":"31","author":"Yamaguchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13075-025-03600-0","article-title":"Anti-interferon-\u03b1 antibodies associate with disease activity and prognosis in anti-MDA5-positive dermatomyositis","volume":"27","author":"Sun","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101446_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10067-023-06816-0","article-title":"Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases","volume":"43","author":"Cheng","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/mr\/roac091","article-title":"Differences in sex-and age-associated mortality in patients with anti-MDA5-positive dermatomyositis","volume":"33","author":"He","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib29","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1093\/rheumatology\/keae466","article-title":"Comparative B cell epitope profiling in Japanese and North American cohorts of MDA5+ dermatomyositis patients reveals a direct association between immune repertoire and pulmonary mortality","volume":"64","author":"Yamaguchi","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib30","first-page":"193","article-title":"Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study","volume":"43","author":"Faria","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib31","doi-asserted-by":"crossref","first-page":"A1832","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1832","article-title":"Characterization of MDA5-ILD in a predominantly Hispanic population of south Florida","volume":"211","author":"Villamizar","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101446_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.resinv.2026.101446_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.resinv.2026.101446_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040605","article-title":"A retrospective study for clinical characteristics of 293 patients with dermatomyositis","volume":"103","author":"Xie","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.resinv.2026.101446_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.765140","article-title":"ECG changes through immunosuppressive therapy indicate cardiac abnormality in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis","volume":"12","author":"Matsuo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib36","article-title":"Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis\/clinically amyopathic dermatomyositis: a retrospective study","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib37","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140\u2010kd polypeptide, CADM\u2010140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2026.101446_bib38","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/rheumatology\/keac450","article-title":"Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China","volume":"62","author":"You","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fmed.2020.00363","article-title":"Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: a series of 474 patients","volume":"7","author":"Li","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib41","article-title":"Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib42","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1093\/rheumatology\/keac094","article-title":"Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis","volume":"61","author":"So","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmcr.2024.102072","article-title":"Asymptomatic and slowly progressive anti-MDA5 ILD: a report of three cases deviating from a notoriously rapidly progressive ILD","volume":"51","author":"Puthumana","year":"2024","journal-title":"Respiratory medicine case reports"},{"key":"10.1016\/j.resinv.2026.101446_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2026.101446_bib46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib47","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.resinv.2018.07.007","article-title":"Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis","volume":"56","author":"Sakamoto","year":"2018","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2026.101446_bib48","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","article-title":"Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis","volume":"29","author":"Nishioka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib49","article-title":"Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5+ dermatomyositis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/rheumatology\/keab268","article-title":"Distribution of anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5+ dermatomyositis","volume":"61","author":"Chen","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib51","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/kead550","article-title":"Correlation between B-cell epitope profile and clinical features of anti-MDA5 antibody-positive dermatomyositis","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib52","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1093\/rheumatology\/keaa266","article-title":"The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease","volume":"59","author":"Huang","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib53","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1007\/s10067-024-07110-3","article-title":"Dynamic change of lymphocytes associated with short-term prognosis in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multicenter retrospective study","volume":"43","author":"Tian","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/joim.13607","article-title":"Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti\u2010MDA5\u2010positive dermatomyositis","volume":"293","author":"Jin","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.resinv.2026.101446_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.808875","article-title":"Low circulating monocytes is in parallel with lymphopenia which predicts poor outcome in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease","volume":"8","author":"Lv","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib56","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3892\/mmr.2017.6693","article-title":"Potential role of autophagy in T-cell survival in polymyositis and dermatomyositis","volume":"16","author":"Shu","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.resinv.2026.101446_bib57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-024-03415-5","article-title":"Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease","volume":"26","author":"Niu","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101446_bib58","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1378\/chest.08-2740","article-title":"Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis","volume":"136","author":"Mukae","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101446_bib59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12890-022-02106-8","article-title":"Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2026.101446_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1332","article-title":"Prognostic analysis of MDA5\u2010associated clinically amyopathic dermatomyositis with interstitial lung disease","volume":"12","author":"Wang","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.resinv.2026.101446_bib61","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1038\/s41598-023-30595-y","article-title":"The prognostic role of C-reactive protein to albumin ratio and anti-MDA5 antibody-positive in idiopathic inflammatory myopathy: a retrospective study","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2026.101446_bib62","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.41566","article-title":"Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis\u2013associated interstitial lung disease","volume":"73","author":"Gono","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22978","article-title":"Serum KL\u20106 level is a prognostic marker in patients with anti\u2010MDA5 antibody\u2010positive dermatomyositis associated with interstitial lung disease","volume":"33","author":"Ye","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.resinv.2026.101446_bib64","doi-asserted-by":"crossref","first-page":"292","DOI":"10.55563\/clinexprheumatol\/zmn18h","article-title":"Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease","volume":"40","author":"Zhu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib65","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib67","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.2147\/JIR.S462721","article-title":"Liver involvement is associated with higher risk of rapidly progressive interstitial lung disease and mortality in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","author":"Yang","year":"2024","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.resinv.2026.101446_bib68","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s10067-024-07093-1","article-title":"Anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis with liver dysfunction: a warning sign of higher death risk","volume":"43","author":"Mo","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib69","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00296-019-04255-2","article-title":"Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis","volume":"39","author":"Nagashima","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.resinv.2026.101446_bib70","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13075-023-03100-z","article-title":"Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody","volume":"25","author":"Wang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101446_bib72","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","article-title":"HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody","volume":"105","author":"Tanizawa","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101446_bib73","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101446_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","article-title":"Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients","volume":"28","author":"Fujiki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib75","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti\u2013melanoma differentiation\u2013associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.resinv.2026.101446_bib76","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","article-title":"HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients","volume":"34","author":"Zou","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib77","article-title":"A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis","volume":"11","author":"Xu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2026.101446_bib78","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10067-021-06033-7","article-title":"Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study","volume":"41","author":"Yamaguchi","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12931-024-02843-w","article-title":"Radiomics based on HRCT can predict RP-ILD and mortality in anti-MDA5+ dermatomyositis patients: a multi-center retrospective study","volume":"25","author":"He","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2026.101446_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.768052","article-title":"A computed tomography radiomics-based prediction model on interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib81","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/rheumatology\/kead263","article-title":"A nomogram based on clinical factors and CT radiomics for predicting anti-MDA5+ DM complicated by RP-ILD","volume":"63","author":"Li","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.779272","article-title":"Radiological characteristics of patients with anti-MDA5\u2013antibody-positive dermatomyositis in 18F-FDG PET\/CT: a pilot study","volume":"8","author":"Cao","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib83","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1007\/s10067-022-06239-3","article-title":"18F-FDG PET\/CT and HRCT: a combined tool for risk stratification in idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"41","author":"Zhang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib84","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.resinv.2026.101446_bib85","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.42308","article-title":"Identification of three different phenotypes in anti\u2013melanoma differentiation\u2013associated gene 5 antibody\u2013positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib86","doi-asserted-by":"crossref","first-page":"304","DOI":"10.55563\/clinexprheumatol\/df2oc3","article-title":"Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses","volume":"40","author":"Yang","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib87","article-title":"Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2026.101446_bib88","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jdv.20850","article-title":"Risk stratification in anti\u2010MDA5+ dermatomyositis\u2010related interstitial lung disease by using cluster analysis","volume":"40","author":"He","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.resinv.2026.101446_bib89","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae303","article-title":"From machine learning to clinical practice: phenotypic clusters of anti-MDA5 antibody-positive dermatomyositis","volume":"25","author":"Koopman","year":"2024","journal-title":"Briefings Bioinf"},{"key":"10.1016\/j.resinv.2026.101446_bib90","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2169\/internalmedicine.1410-22","article-title":"Early initiation of plasma exchange therapy for anti-MDA5+ dermatomyositis with refractory rapidly progressive interstitial lung disease","volume":"63","author":"Sasaki","year":"2024","journal-title":"Internal Medicine"},{"key":"10.1016\/j.resinv.2026.101446_bib91","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib92","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","article-title":"A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment","volume":"27","author":"Koichi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib93","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.14999","article-title":"Aggressive multi\u2010combination therapy for anti\u2010MDA5 antibody\u2010positive dermatomyositis\u2010rapidly progressive interstitial lung disease","volume":"27","author":"Hata","year":"2024","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.resinv.2026.101446_bib95","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12890-017-0479-2","article-title":"Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias","volume":"17","author":"Okabayashi","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2026.101446_bib96","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","article-title":"Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis","volume":"60","author":"Zhang","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib97","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ard.2025.01.010","article-title":"Refractory MDA-5 dermatomyositis rapidly progressive interstitial lung disease successfully treated with emapalumab","volume":"84","author":"Concepcion","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.resinv.2026.101446_bib98","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"American college of rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib99","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib100","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"Ida","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.resinv.2026.101446_bib102","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101446_bib103","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101446_bib104","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-025-03675-9","article-title":"Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease","volume":"27","author":"Zhu","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2026.101446_bib105","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2391445","article-title":"A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.resinv.2026.101446_bib106","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105983","article-title":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis\/dermatomyositis associated ILD","volume":"172","author":"Mao","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2026.101446_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1472667","article-title":"Mycophenolate mofetil after tacrolimus for refractory clinically amyopathic dermatomyositis: a case report","volume":"15","author":"Ling","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2026.101446_bib109","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1378\/chest.13-0186","article-title":"Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140\/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis","volume":"144","author":"Teruya","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101446_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib111","first-page":"386","article-title":"Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease","volume":"42","author":"Chen","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib112","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10067-022-06422-6","article-title":"Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature","volume":"42","author":"Lian","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib113","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation\u2010associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.resinv.2026.101446_bib114","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/rheumatology\/keac627","article-title":"Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis","volume":"62","author":"Kogami","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2026.101446_bib115","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s10067-019-04729-5","article-title":"Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum","volume":"38","author":"Yamaguchi","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib116","series-title":"Seminars in arthritis and rheumatism","article-title":"Spontaneous pneumomediastinum in anti-MDA5-positive dermatomyositis: prevalence, risk factors, and prognosis","author":"Jin","year":"2024"},{"key":"10.1016\/j.resinv.2026.101446_bib117","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12931-025-03347-x","article-title":"Spontaneous pneumomediastinum and\/or pneumothorax in anti-MDA5 dermatomyositis: a refined staging system","volume":"26","author":"Jin","year":"2025","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2026.101446_bib118","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3390\/biomedicines10123176","article-title":"Infection risk in patients with dermatomyositis associated with anti-MDA5 antibodies: a historical cohort study","volume":"10","author":"Billet","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.resinv.2026.101446_bib119","first-page":"218","article-title":"Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis","volume":"44","author":"Yang","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib120","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/JIR.S460702","article-title":"Prevalence, risk factors, and mortality of invasive pulmonary aspergillosis in patients with anti-MDA5+ dermatomyositis: a retrospective study in China","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.resinv.2026.101446_bib121","first-page":"237","article-title":"Expansion of exhausted CD8+ T cells associates with increased pulmonary fungal infection risk in anti-melanoma differentiation associated gene 5 dermatomyositis","volume":"42","author":"Xu","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.resinv.2026.101446_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.740154","article-title":"Association of cytomegalovirus infection with anti-MDA5 antibody-positive dermatomyositis: a prospective cohort study","volume":"8","author":"Huang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2026.101446_bib123","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s10067-025-07445-5","article-title":"Severe infection risk in triple and quadruple therapy for anti-MDA5 antibody-positive dermatomyositis","volume":"44","author":"Ueda","year":"2025","journal-title":"Clin Rheumatol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526000808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:40:25Z","timestamp":1784029225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526000808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2212534526000808"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101446","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features, pathogenesis, and treatment of anti-MDA5 antibody-positive interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101446"}}